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Introduction {#sec1}
============

Mononuclear phagocytes play a central role in the initiation and resolution of innate and adaptive immune responses. They comprise several populations of monocytes, macrophages, and dendritic cells (DCs), which are classically defined by their phenotype and ontogeny ([@bib9]). Monocytes are very plastic cells and can differentiate into cells displaying typical features of macrophages or DCs, referred to as monocyte-derived macrophages (mo-Mac) and monocyte-derived DCs (mo-DC). This phenomenon has been described *in vitro* and *in vivo*, in both mouse and human ([@bib10], [@bib3], [@bib7]). Recently, high-resolution single-cell technologies have revealed a new subset of blood DCs, termed DC3, displaying a mixed transcriptomic profile of classical DC (cDC) and monocyte genes ([@bib2], [@bib6], [@bib20]), reminiscent of that of mo-DC ([@bib18], [@bib8]). Whether blood DC3 represent circulating mo-DC has been unclear.

Accumulating evidence suggests that monocyte-derived cells are involved in the pathogenesis of autoimmune and chronic inflammatory diseases ([@bib3]). However, their characterization in inflamed tissues is complicated by the promiscuous expression of numerous phenotypic markers, shared in particular with macrophages and cDCs. More specific markers are needed in order to advance our understanding of the respective properties of macrophages, cDCs, and mo-DC, and ultimately to allow the manipulation of these cells for therapeutic strategies.

To identify novel markers for human mo-DC, we have used a synthetic library of humanized llama single domain antibodies. We identified one antibody, recognizing surface LSP-1, that stains specifically mo-DC, but not monocytes, macrophages, cDCs, or DC3.

Results {#sec2}
=======

In order to identify novel surface markers for human naturally occurring mo-DC, we set up a phage display screen using a synthetic library of humanized llama single domain antibodies (termed VHH) ([@bib16]). We have previously shown that peritoneal ascites from patients with cancer contain a population of mo-DC ([@bib18], [@bib19]). Cells from tumor ascites were separated into DCs and all other cells (non-DCs), including tumor cells, macrophages, T cells, and other immune cells. The library was first depleted for phages binding to non-DCs, then phages binding to ascites DCs were screened ([Figure 1](#fig1){ref-type="fig"}A). For subsequent studies, we produced the VHH of interest with a human Fc region containing a streptavidin-binding peptide. Using this strategy, we identified a VHH antibody, termed "D4," that stains ascites DCs but not macrophages from the same samples ([Figure 1](#fig1){ref-type="fig"}B). We have recently reported a culture model allowing the generation of *in vitro* counterparts of naturally occurring mo-DC and mo-Mac, by culturing CD14^+^ monocytes with M-CSF, IL-4, and TNFα ([@bib8]). In this model, the VHH D4 stained mo-DC but not mo-Mac ([Figure 1](#fig1){ref-type="fig"}C). We have also shown that the classical model of culturing monocytes with GM-CSF and IL-4 generates mo-DC that do not closely resemble the ones found *in vivo* in inflammatory fluids ([@bib8]). Consistent with this, the VHH D4 did not stain mo-DC generated with GM-CSF and IL-4 ([Figure 1](#fig1){ref-type="fig"}C).Figure 1Identification of a VHH Specific for Monocyte-Derived Dendritic Cells(A) Strategy for identifying novel surface markers for ascites dendritic cells (DCs).(B) Ascites cells were stained with VHH D4. Stainings for DC and macrophages (Macro) are shown (representative of five individual donors). Gray shaded histograms are fluorescence-minus-one controls.(C) Monocytes were cultured with M-CSF, IL-4, and TNFa to generate DC (mo-DC) and macrophages (mo-Mac) or with GM-CSF and IL-4 to generate DC (GM + IL4 mo-DC). Cells were stained with VHH D4. Gray shaded histograms are fluorescence-minus-one controls. Representative of four individual donors.

We then sought to address whether the VHH D4 could also stain other myeloid cells, in particular cDCs. We first used the VHH D4 on cells isolated from human tonsils. We have previously shown using single-cell RNA sequencing (RNA-seq) analysis that tonsils contain cDC1 (CD141^high^CD1c^−^ DCs) and cDC2 (CD141^low^CD1c^+^ DCs), but no population of mo-DC ([@bib5]). There was no significant staining of VHH D4 on cDC1, cDC2, or tonsil macrophages ([Figure 2](#fig2){ref-type="fig"}A). This result suggests that the VHH D4 is specific of mo-DC and does not stain cDCs.Figure 2VHH D4 Does Not Stain Classical Dendritic Cell Populations(A) Tonsil DC and macrophages were stained with VHH D4. Gray shaded histograms are fluorescence-minus-one controls. Representative of two individual donors. Peripheral blood cells (B and C) or ascites cells (C) were stained with VHH D4. Gray shaded histograms are fluorescence-minus-one controls. Representative of five (blood) or four (ascites) individual donors. (C) Gating strategy for analyzing HLA-DR^+^ cells, including CD14^+^ monocytes, cDC2, and DC3, is shown. Staining of ascites DC is shown as a positive control.

To extend these observations, we stained peripheral blood cells. There was no significant staining on plasmacytoid DCs (pDC), B cells, granulocytes, NK cells, or T cells ([Figure 2](#fig2){ref-type="fig"}B). We further dissected VHH D4 staining on myeloid cells ([Figure 2](#fig2){ref-type="fig"}C). Blood monocytes comprise three subpopulations defined by their expression of CD16 and CD14. In addition, it has recently been shown that blood CD1c^+^ DCs are heterogeneous and comprise CD1c^+^CD14^−^CD163^−^ DCs (*bona fide* cDC2) and CD1c^+^CD14^+^CD163^+^ DCs, termed DC3 ([@bib1], [@bib2], [@bib6], [@bib20]). The VHH D4 did not show a significant staining on blood monocytes, cDC2, DC3, or other CD19^−^HLA-DR^+^ cells ([Figure 2](#fig2){ref-type="fig"}C). These results confirm that VHH D4 does not recognize cDCs or other blood leukocyte populations.

To determine the target of VHH D4 on the surface of mo-DC, we performed immuno-precipitation followed by proteomics mass spectrometry, using *in vitro*-generated mo-DC (cultured with M-CSF, IL-4, and TNFα) as a source of material. Mass spectrometry identified only one protein: Lymphocyte-Specific Protein 1 (LSP-1), a protein of predicted molecular weight of 60 kDa. To validate this result, we performed immuno-precipitation with VHH D4 on *in vitro*-generated mo-DC and mo-Mac and revealed the immuno-precipitated proteins using streptavidin ([Figure 3](#fig3){ref-type="fig"}A) or a commercial anti-LSP-1 antibody ([Figure 3](#fig3){ref-type="fig"}B). Both methods showed the same band around 55 kDa, only in immuno-precipitated material from mo-DC. This observation confirms that the VHH D4 binds LSP-1.Figure 3Identification of LSP-1 as the Target of VHH D4*In vitro*-generated mo-DC or mo-Mac were incubated with VHH D4, then lysed. Immuno-precipitation was performed on cell lysate using the streptavidin-binding peptide tag. MW, molecular weight. Immuno-precipitated material was analyzed by western blot. Staining was performed using streptavidin-HRP (A) or a commercial anti-LSP-1 antibody (B).

LSP-1 is an F-actin binding protein reported to be expressed in all leukocytes ([@bib17]). Using our previously generated transcriptomic data ([@bib8]), we confirmed that *LSP1* was expressed at similar levels in ascites mo-DC; ascites macrophages; *in vitro* mo-DC and mo-Mac generated with M-CSF, IL-4, and TNFα; *in vitro* mo-DC generated with GM-CSF and IL-4; and blood monocytes ([Figure 4](#fig4){ref-type="fig"}A). Using transcriptomic data from the Human Cell Atlas, we also observed that *LSP1* was expressed in all blood leukocytes, with myeloid cells displaying the highest levels ([Figure 4](#fig4){ref-type="fig"}B). To confirm the intracellular expression of LSP-1, we performed flow cytometry on permeabilized cells using either a commercial anti-LSP1 antibody or VHH D4. Although the commercial anti-LSP1 did not show any surface staining (including on mo-DC), it detected intracellular LSP1 in blood myeloid cells and *in vitro*-generated mo-DC and mo-Mac ([Figure 4](#fig4){ref-type="fig"}C). By contrast, VHH D4 did not stain intracellular LSP1 in blood myeloid cells or mo-Mac and mo-DC ([Figure 4](#fig4){ref-type="fig"}D). These results suggest that VHH D4 recognizes a surface epitope of LSP-1 that is specifically expressed by mo-DC.Figure 4VHH D4 Recognizes a Surface Epitope of LSP-1 Specifically Expressed by mo-DC(A) Expression levels (arbitrary units) of *LSP1* in ascites DC; ascites macrophages; *in vitro* mo-DC and mo-Mac generated with M-CSF, IL-4, and TNFα; *in vitro* mo-DC generated with GM-CSF and IL-4; and blood CD14^+^ monocytes. Each dot represents an individual donor. Median is shown. Affymetrix data from dataset [GSE102046](ncbi-geo:GSE102046){#intref0020}.(B) Normalized counts of *LSP1* expression in selected human blood cells. RNA-seq data from the Human Cell Atlas (<http://immunecellatlas.net>).(C and D) Monocytes were cultured with M-CSF, IL-4, and TNFα to generate DC (mo-DC) and macrophages (mo-Mac). Peripheral blood myeloid cells were also analyzed (monocytes and cDC2). Cells were stained with a commercial anti-LSP-1 antibody (C) or VHH D4 (D), with membrane permeabilization (intracellular) or not (surface). Gray shaded histograms are fluorescence-minus-one controls. Representative of five (blood) or six (*in vitro*-generated) individual donors.

Discussion {#sec3}
==========

Using a synthetic library of humanized llama single domain antibodies, we have identified one antibody, recognizing LSP-1, that is specific for human mo-DC and distinguishes them from monocytes, macrophages, cDCs, or DC3.

LSP-1 has been shown so far to reside on the cytoplasmic side of the plasma membrane ([@bib12]). After membrane permeabilization, LSP-1 can be detected by flow cytometry, consistent with previous work ([@bib17]). Because VHH D4 stains mo-DC without membrane permeabilization, our results suggest the existence of an extra-cellular domain of LSP-1 specifically in mo-DC. The VHH D4 stains both mo-DC found *in vivo* in tumor ascites and generated *in vitro* with M-CSF, IL-4, and TNFα, indicating that the expression of a surface domain of LSP-1 is not due to the inflammatory micro-environment, but rather could be the result of a mo-DC core transcriptional program. Whether surface LSP-1 results from alternative splicing or another post-transcriptional mechanism remains open for future investigation.

DC3 express a mixed transcriptional program with hallmark cDC2 genes (such as *FCER1A, CD1C, CLEC10A*) as well as typical monocyte gene*s* (such as *S100A8*, *S100A9*, *VCAN*) ([@bib2], [@bib6], [@bib20]), raising the question of their ontogeny, in particular whether DC3 correspond to circulating mo-DC. Our results add to different lines of evidence suggesting that DC3 are distinct from mo-DC. Blood cDC2 and DC3, but not monocytes, were increased upon injection of Flt3-ligand to patients with lymphoma ([@bib6]). In addition, *in vitro* differentiation assays and analysis of an allelic series of human IRF8 deficiency suggested that DC3 and monocytes derive from a common progenitor but along distinct differentiation pathways ([@bib4]). Here, we did not observe a significant staining of VHH D4 on blood DC3, showing that the phenotype of DC3 is distinct from that of ascites mo-DC. This is consistent with the hypothesis that DC3 do not represent circulating blood mo-DC.

Together with our previous phenotypic characterization of mo-DC ([@bib8]) and recent single-cell analysis of blood cDC2, DC3, and monocytes ([@bib6], [@bib20]), our work enables a more precise phenotypic definition of human DC subsets. cDC2 can be defined as CD88^−^CD14^−^CD1c^+^FcεRI^+^CD226^−^CD163^−^sLSP-1^-^, DC3 as CD88^−^CD14^+^CD1c^+^FcεRI^+^CD226^−^CD163^+^sLSP-1^−^, and mo-DC as CD88^low^CD14^+^CD1c^+^FcεRI^+^CD226^+^CD163^−^sLSP-1^+^.

Mo-DC have been identified in several inflammatory contexts in human tissues ([@bib3]). In cancer, the picture is less clear as DCs displaying a phenotype consistent with both mo-DC and DC3 have been reported in colorectal, breast, and lung tumors ([@bib13], [@bib14], [@bib15]). DC3 are increased in the blood of patients with melanoma ([@bib2]) and systemic lupus erythematosus ([@bib6]), whereas blood DC3 infiltrate the lung alveolar space upon LPS-induced acute inflammation ([@bib11]). The respective role of these two DC subtypes in cancer or inflammation remains elusive. Our findings will pave the way for a better characterization of DC3 and mo-DC in pathological settings, ultimately allowing their manipulation for therapeutic strategies.

Limitations of the Study {#sec3.1}
------------------------

In this work, we have identified one antibody (VHH D4) that is specific for human mo-DC present in ascites or derived *in vitro* from monocytes using a combination of M-CSF, IL-4, and TNFα. Further work is needed to address whether VHH D4 also stains the mo-DC that have been described in other human tissues, such as skin, lung, or gut. In addition, complementary markers, such as defined in the [Discussion](#sec3){ref-type="sec"}, should be used for the accurate identification of myeloid cells in human tissues.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Data and Code Availability {#appsec1}
==========================

Proteomics data are available via ProteomeXchange (identifier [PXD015647](pride:PXD015647){#intref0010}).
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